MA55201A - Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire - Google Patents
Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaireInfo
- Publication number
- MA55201A MA55201A MA055201A MA55201A MA55201A MA 55201 A MA55201 A MA 55201A MA 055201 A MA055201 A MA 055201A MA 55201 A MA55201 A MA 55201A MA 55201 A MA55201 A MA 55201A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pathway inhibitors
- chronic lung
- lung allograft
- allograft dysfunction
- Prior art date
Links
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 210000004072 lung Anatomy 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814085P | 2019-03-05 | 2019-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55201A true MA55201A (fr) | 2022-01-12 |
Family
ID=69941525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055201A MA55201A (fr) | 2019-03-05 | 2020-03-05 | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11406640B2 (fr) |
| EP (1) | EP3934651A1 (fr) |
| JP (2) | JP2022524997A (fr) |
| KR (1) | KR20210137087A (fr) |
| CN (1) | CN114007621A (fr) |
| AU (1) | AU2020232757B2 (fr) |
| CA (1) | CA3132371A1 (fr) |
| EA (1) | EA202192426A1 (fr) |
| IL (1) | IL285999B1 (fr) |
| MA (1) | MA55201A (fr) |
| MX (2) | MX2021010545A (fr) |
| PH (1) | PH12021552130A1 (fr) |
| SG (1) | SG11202109563WA (fr) |
| WO (1) | WO2020181034A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021004052A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas de dimetil-amino azetidina como inibidores de jak |
| SG11202101751XA (en) | 2018-09-04 | 2021-03-30 | Theravance Biopharma R&D Ip Llc | 5 to 7 membered heterocyclic amides as jak inhibitors |
| MX2021004582A (es) | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
| CN113490484B (zh) | 2018-10-31 | 2024-08-23 | 因赛特公司 | 治疗血液疾病的组合疗法 |
| JP2022524997A (ja) | 2019-03-05 | 2022-05-11 | インサイト・コーポレイション | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| KR20230053831A (ko) | 2021-10-15 | 2023-04-24 | 주식회사 엘지에너지솔루션 | 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4188078B2 (ja) | 2000-06-28 | 2008-11-26 | スミスクライン ビーチャム ピー エル シー | 湿式粉砕法 |
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| US20070219223A1 (en) | 2006-03-07 | 2007-09-20 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| DK2740731T3 (en) | 2007-06-13 | 2016-04-11 | Incyte Holdings Corp | CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL |
| EP3195862A1 (fr) | 2008-04-17 | 2017-07-26 | Sanofi | Utilisation de la dronedarone dans la preparation d'un medicament utilise pour prevenir un episode cardiovasculaire menant a l'hospitalisation ou prevenir la fibrillation auriculaire |
| MY156727A (en) | 2009-05-22 | 2016-03-15 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| PL2506716T3 (pl) | 2009-12-01 | 2017-10-31 | Abbvie Inc | Nowe związki tricykliczne |
| AU2011224484A1 (en) | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| AU2011311867A1 (en) | 2010-10-08 | 2013-04-18 | Abbvie Inc. | Furo(3,2-d)pyrimidine compounds |
| EP2640723A1 (fr) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Dérivés pyrrolopyridine et pyrrolopyrimidine à substitution cyclobutyle utilisés comme inhibiteurs des jak |
| WO2012068440A1 (fr) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Pyrrolopyridines et pyrrolopyrimidines à substitution hétérocyclique utilisées en tant qu'inhibiteurs des jak |
| KR20140040819A (ko) | 2011-06-20 | 2014-04-03 | 인사이트 코포레이션 | Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013173720A1 (fr) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak |
| EA201492287A1 (ru) | 2012-06-15 | 2015-07-30 | Консерт Фармасьютикалс, Инк. | Дейтерированные производные руксолитиниба |
| MX361499B (es) | 2012-08-17 | 2018-12-06 | Concert Pharmaceuticals Inc | Baricitinib deuterado. |
| UA117572C2 (uk) | 2012-11-01 | 2018-08-27 | Інсайт Холдинґс Корпорейшн | Трициклічні конденсовані похідні тіофену як інгібітори jak |
| JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤の製造方法及びその中間体 |
| TWI719401B (zh) | 2013-05-17 | 2021-02-21 | 美商英塞特公司 | 作為jak抑制劑之聯吡唑衍生物 |
| KR20160045081A (ko) * | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
| AU2014339897A1 (en) * | 2013-10-24 | 2016-04-21 | Abbvie Inc. | JAK1 selective inhibitor and uses thereof |
| CN106456773A (zh) * | 2014-02-28 | 2017-02-22 | 因赛特公司 | 用于治疗骨髓增生异常综合征的jak1抑制剂 |
| MX2016014192A (es) | 2014-04-30 | 2017-05-01 | Incyte Corp | Procesos para preparar un inhibidor de cinasas de janus 1 (jak1) y nuevas formas de este. |
| WO2015184305A1 (fr) | 2014-05-30 | 2015-12-03 | Incyte Corporation | Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1 |
| WO2017079205A1 (fr) | 2015-11-03 | 2017-05-11 | Theravance Biopharma R&D Ip, Llc | Composés inhibiteurs de kinase jak pour le traitement de maladies respiratoires |
| CN105294699B (zh) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
| HUE058120T2 (hu) * | 2016-10-03 | 2022-07-28 | Highlightll Pharmaceutical Hainan Co Ltd | Új JAK1-szelektív inhibitorok és alkalmazásuk |
| EP3327020A1 (fr) * | 2016-11-29 | 2018-05-30 | Sandoz Ag | Sels de citrate d'un inhibiteur de kinase de janus (jak) |
| JP6974487B2 (ja) | 2017-03-09 | 2021-12-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ４員ヘテロ環式アミドを含むｊａｋ阻害剤 |
| US10406148B2 (en) | 2017-05-01 | 2019-09-10 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
| BR112020016628A2 (pt) | 2018-02-16 | 2020-12-15 | Incyte Corporation | Inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| SG11202010092XA (en) | 2018-04-13 | 2020-11-27 | Incyte Corp | Biomarkers for graft-versus-host disease |
| CN113490484B (zh) | 2018-10-31 | 2024-08-23 | 因赛特公司 | 治疗血液疾病的组合疗法 |
| PH12021551455A1 (en) | 2018-12-19 | 2022-04-18 | Incyte Corp | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| JP2022524997A (ja) | 2019-03-05 | 2022-05-11 | インサイト・コーポレイション | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
-
2020
- 2020-03-05 JP JP2021552624A patent/JP2022524997A/ja active Pending
- 2020-03-05 CA CA3132371A patent/CA3132371A1/fr active Pending
- 2020-03-05 SG SG11202109563WA patent/SG11202109563WA/en unknown
- 2020-03-05 MA MA055201A patent/MA55201A/fr unknown
- 2020-03-05 CN CN202080024215.0A patent/CN114007621A/zh active Pending
- 2020-03-05 AU AU2020232757A patent/AU2020232757B2/en active Active
- 2020-03-05 WO PCT/US2020/021088 patent/WO2020181034A1/fr not_active Ceased
- 2020-03-05 EP EP20713496.6A patent/EP3934651A1/fr active Pending
- 2020-03-05 MX MX2021010545A patent/MX2021010545A/es unknown
- 2020-03-05 KR KR1020217031644A patent/KR20210137087A/ko active Pending
- 2020-03-05 PH PH1/2021/552130A patent/PH12021552130A1/en unknown
- 2020-03-05 EA EA202192426A patent/EA202192426A1/ru unknown
- 2020-03-05 IL IL285999A patent/IL285999B1/en unknown
- 2020-03-05 US US16/810,045 patent/US11406640B2/en active Active
-
2021
- 2021-09-02 MX MX2024007081A patent/MX2024007081A/es unknown
-
2022
- 2022-06-30 US US17/854,443 patent/US11896595B2/en active Active
-
2025
- 2025-02-21 JP JP2025026650A patent/JP2025087734A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3132371A1 (fr) | 2020-09-10 |
| CN114007621A (zh) | 2022-02-01 |
| US20220331325A1 (en) | 2022-10-20 |
| IL285999A (en) | 2021-10-31 |
| IL285999B1 (en) | 2025-09-01 |
| WO2020181034A1 (fr) | 2020-09-10 |
| MX2024007081A (es) | 2024-06-21 |
| EA202192426A1 (ru) | 2021-11-15 |
| MX2021010545A (es) | 2021-11-17 |
| SG11202109563WA (en) | 2021-09-29 |
| US11896595B2 (en) | 2024-02-13 |
| US11406640B2 (en) | 2022-08-09 |
| JP2025087734A (ja) | 2025-06-10 |
| US20200281931A1 (en) | 2020-09-10 |
| AU2020232757B2 (en) | 2025-09-11 |
| AU2020232757A1 (en) | 2021-10-07 |
| KR20210137087A (ko) | 2021-11-17 |
| JP2022524997A (ja) | 2022-05-11 |
| EP3934651A1 (fr) | 2022-01-12 |
| PH12021552130A1 (en) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55201A (fr) | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire | |
| MA51829A (fr) | Inhibiteurs de la voie jak1 pour le traitement de troubles liés aux cytokines | |
| MA54544A (fr) | Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale | |
| EP3600281A4 (fr) | Traitement d'association pour le traitement ou la prévention de tumeurs | |
| IL292690A (en) | mrgprx2 antagonists for the treatment of inflammatory disorders | |
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3737361A4 (fr) | Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie | |
| EP3700516A4 (fr) | Inhibiteurs de l'induction de dux4 pour la régulation de la fonction musculaire | |
| EP3434291A4 (fr) | Composition pour le traitement d'un disque intervertébral | |
| EP3969111A4 (fr) | Formulations inhalables pour l'inhibition de kinases | |
| EP3630287A4 (fr) | Inhibiteurs de parp radiomarqués et fluorescents pour l'imagerie et la radiothérapie | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
| EP3877402A4 (fr) | Traitement combiné pour l'hypertension résistante | |
| EP3863671A4 (fr) | Anticorps monoclonal pour le traitement de la leucémie lymphoblastique aiguë | |
| EP3898991A4 (fr) | Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative | |
| EP3687537A4 (fr) | Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple | |
| EP3810091A4 (fr) | Méthodes et compositions pour le traitement de l'hypertension pulmonaire | |
| MA55486A (fr) | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial | |
| EP3541379A4 (fr) | Compositions pour le traitement de l'hypertension | |
| EP3843737A4 (fr) | Inhibiteurs de pde9 pour le traitement de la drépanocytose | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3931178A4 (fr) | Composés pour la prévention et le traitement d'un dysfonctionnement cognitif post-opératoire | |
| EP4073060A4 (fr) | Inhibiteurs de l'histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs |